Akari Therapeutics Plc
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized**.**
| Akari Therapeutics, Plc | ||
| Date: March 30, 2026 | By: | /s/ Abizer Gaslightwala |
|---|---|---|
| Abizer Gaslightwala | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Abizer Gaslightwala | President and Chief Executive Officer | March 30, 2026 |
| Abizer Gaslightwala | (principal executive officer) | |
| /s/ Kameel Farag | Interim Chief Financial Officer | March 30, 2026 |
| Kameel Farag | (principal financial officer and principal accounting officer) | |
| /s/ Hoyoung Huh, M.D., Ph.D. | Chairman | March 30, 2026 |
| Hoyoung Huh, M.D., Ph.D. | ||
| /s/ Ray Prudo, M.D. | Director | March 30, 2026 |
| Ray Prudo, M.D. | ||
| /s/ James Neal | Director | March 30, 2026 |
| James Neal | ||
| /s/ Sandip I. Patel | Director | March 30, 2026 |
| Sandip I. Patel | ||
| /s/ Robert Bazemore | Director | March 30, 2026 |
| Robert Bazemore | ||
| /s/ Samir R. Patel, M.D. | Director | March 30, 2026 |
| Samir R. Patel, M.D. | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (BDO USA, P.C.; New York, New York; PCAOB ID# 243) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F-5 |
| Consolidated Statements of Operations and Comprehensive Loss for the Years ended December 31, 2025 and 2024 | F-6 |
| Consolidated Statements of Shareholders’ Equity (Deficit) for the Years ended December 31, 2025 and 2024 | F-7 |
| Consolidated Statements of Cash Flows for the Years ended December 31, 2025 and 2024 | F-8 |
| Notes to Consolidated Financial Statements | F-10 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.